Open AccessThe splicing factor DHX38/PRP16 is required for ovarian clear cell carcinoma tumorigenesis, as revealed by a CRISPR‐Cas9 screen
Author(s) -
Cona Brandon,
Hayashi Tomoatsu,
Yamada Ai,
Shimizu Naomi,
Yokota Naoko,
Nakato Ryuichiro,
Shirahige Katsuhiko,
Akiyama Tetsu
Publication year - 2022
Publication title -
febs open bio
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.718
H-Index - 31
ISSN - 2211-5463
DOI - 10.1002/2211-5463.13358
Subject(s) - carcinogenesis , cancer research , biology , clear cell carcinoma , rna splicing , crispr , gene knockdown , clear cell , small hairpin rna , gene , cell , cell growth , cell culture , cancer , carcinoma , genetics , rna
Certain cancers, such as ovarian clear cell carcinoma (OCCC), display high levels of genetic variation between patients, making it difficult to develop effective therapies. In order to identify novel genes critical to OCCC growth, we carried out a comprehensive CRISPR‐Cas9 knockout screen against cell growth using an OCCC cell line and a normal ovarian surface epithelium cell line. We identified the gene encoding DHX38/PRP16, an ATP‐dependent RNA helicase involved in splicing, as critical for the growth and tumorigenesis of OCCC. DHX38/PRP16 knockdown in OCCC cells, but not normal cells, induces apoptosis and impairs OCCC tumorigenesis in a mouse model. Our results suggest that DHX38/PRP16 may play a role in OCCC tumorigenesis and could potentially be a promising therapeutic target.